

CLAIMS

The listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously Amended) A method of blocking an immune response to a foreign graft in a mammal, where the mammal is not suffering from a malignancy, comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.

2-4. (Cancelled)

5. (Original) The method of claim 1 wherein the mammal is human.

6. (Previously Amended) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

7. (Previously Amended) The method of claim 1 wherein the antibody comprises rituximab.

8. (Previously Amended) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.

9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.

10. (Previously Amended) The method of claim 9 wherein the antibody comprises Y2B8 or ^{131}I -B1.

11. (Previously Amended) The method of claim 1 comprising administering the antibody intravenously.

12. (Previously Amended) The method of claim 1 comprising administering the antibody subcutaneously.

13. (Currently Amended) The method of claim 1, comprising administering a dose of substantially from about 20mg/m² to less than 375mg/m² of the antibody to the mammal.

14. (Original) The method of claim 13 wherein the dose is in the range from about 20mg/m² to about 250mg/m².

15. (Original) The method of claim 14 wherein the dose is in the range from about 50mg/m² to about 200mg/m².

16. (Previously Amended) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m² dose of the antibody in the subsequent dose exceeds the mg/m² dose of the antibody in the initial dose.

17-21. (Cancelled)

22. (Previously Amended) The method of claim 1 comprising administering the antibody to the mammal before the mammal is exposed to the graft.

23-27. (Cancelled)

28. (Previously Amended) A method of treating graft-versus-host or host-versus-graft disease in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.

29-31. (Cancelled)